Literature DB >> 16738361

Inconsistencies in cardiovascular data from COX-2 inhibitor trials--is it a class effect?

Mark Weatherall, Sarah Aldington, Brent Caldwell, Richard Beasley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16738361      PMCID： PMC1472727          DOI： 10.1177/014107680609900604

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  9 in total

1.  Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.

Authors:  J M Wright; T L Perry; K L Bassett; G K Chambers
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

2.  Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.

Authors:  J B Hrachovec; M Mora
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

3.  Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Authors:  Peter Jüni; Anne W S Rutjes; Paul A Dieppe
Journal:  BMJ       Date:  2002-06-01

4.  Celecoxib and the CLASS trial: data massaging by industry.

Authors: 
Journal:  Prescrire Int       Date:  2002-12

5.  Expression of concern reaffirmed.

Authors:  Gregory D Curfman; Stephen Morrissey; Jeffrey M Drazen
Journal:  N Engl J Med       Date:  2006-02-22       Impact factor: 91.245

6.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

7.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

8.  Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.

Authors:  William B White; Gerald Faich; Andrew Whelton; Clement Maurath; Nancy J Ridge; Kenneth M Verburg; G Steven Geis; James B Lefkowith
Journal:  Am J Cardiol       Date:  2002-02-15       Impact factor: 2.778

Review 9.  Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.

Authors:  Brent Caldwell; Sarah Aldington; Mark Weatherall; Philippa Shirtcliffe; Richard Beasley
Journal:  J R Soc Med       Date:  2006-03       Impact factor: 18.000
  9 in total
  1 in total

1.  Complicity theory: an explanation for the 'coxib problem'?

Authors:  Paul Dieppe
Journal:  J R Soc Med       Date:  2006-06       Impact factor: 18.000
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.